Table 3.

Hazard ratios for all-cause mortality at 7,6 years follow-up in 671 CMV seropositive hospitalised elderly patients.

	Adjusted HR	p value
Model 1a
High vs. lowest antibody levels	1.46 (1.11–1.90)	.005
Middle vs. lowest antibody levels	1.33 (1.06–1.68)	.014
High/middle vs. lowest antibody levels	1.37 (1.10–1.71)	.005
Model 2b
High vs. lowest antibody levels	1.51 (1.14–2.00)	.003
Middle vs. lowest antibody levels	1.46 (1.15–1.81)	.002
High/middle vs. lowest antibody levels	1.49 (1.18–1.86)	.001
Model 3c
High vs. lowest antibody levels	1.40 (1.05–1.86)	.019
Middle vs. lowest antibody levels	1.42 (1.11–1.81)	.004
High/middle vs. lowest antibody levels	1.41 (1.12–1.77)	.003

^aModel 1: bivariate relation with mortality.

^bModel 2: include age (>81 years) and gender.

^cModel 3: covariates associated with anti-CMV IgG levels and mortality included: serum albumin levels (<2900 mg/dL), stroke and heart failure.